Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc.

Overview
Date Founded

2007

Headquarters

50 TICE BOULEVARD SUITE 315 WOODCLIFF LAKE NJ 07677

Type of Company

Public

Employees (Worldwide)

106

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Contact Data
Trying to get in touch with decision makers at Eagle Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

President/Chief Commercial Officer

Chief Financial Officer

Executive Vice President, Chief Medical Officer

US Head of Sales

Chief Strategy Officer & Head of Corporate Development

Executive Vice President, Marketing for Oncology & Acute Care

Senior Director

Senior Vice President-Research & Development

Vice President

Board of Directors

Executive Chairman at Nanocopoeia, Inc.

Chair, Litigation Practice at Greenberg Traurig LLP

Chief Financial Officer & President-Financial Services Division at Hackensack Meridian Health, Inc.

Former Chief Financial Officer & Executive Vice President at Brown-Forman Corp.

Director, President & Chief Executive Officer at Panbela Therapeutics, Inc.

Founder at Eagle Pharmaceuticals, Inc.

Senior Fellow for Global Health at Council on Foreign Relations

Paths to Eagle Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Eagle Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

PWAM employs an opportunistic investment strategy. The firm generally pursues three main hedge fund strategies: long/short (hedged equity) investing, event-driven investing and credit/high yield investing. While the firm focuses on these strategies, they may engage in other strategies from time-to-time to take advantage of changing market conditions and other investment opportunities.

Details Hidden

Armistice Capital is a global, long/short, value-oriented and event-driven hedge fund firm which focuses primarily on the health care and consumer sectors. They invest predominantly in equities and can be opportunistic across the capital structure. The firm seeks to maximize the opportunity set of investment candidates allowing for the selection of unique, concentrated bets to generate uncorrelated returns. They maintain significant position and portfolio level hedges in an effort to mitigate basis and market risks. Armistice Capital employs a bottom-up analysis, assessing all components of the company’s capital structure and aims to take larger positions where the greatest potential risk adjusted return exists. Armistice Capital’s Domestic Fund and the Offshore Fund, through their investments in the Master Fund, seek to achieve long-term capital appreciation by employing an opportunistic global long/short strategy for investing in distressed debt, value equities and event equities. In all of its investing activities, the Funds will seek to emphasize capital preservation and will seek to mitigate risk through various hedging strategies at both the position and portfolio levels.

Details Hidden

Smith, Graham & Co. Investment Advisors, L.P. is an SEC registered investment advisory firm. Founded over twenty years ago, we specialize in managing fixed income and equity assets for institutional clients. Smith Graham’s mission is to provide superior investment management services which surpass client objectives while adhering to the highest standards of discipline and integrity. We recognize that the success of our firm is based on our ability to deliver consistent investment outperformance to our clients. The business model that we employ to excel at meeting our clients' investment goals and objectives has four cornerstones. The first cornerstone is our commitment to attracting the brightest and most experienced professionals in the industry. The second cornerstone is our investment teams' adherence to investment philosophies that are well articulated and relevant to the actual workings of the world's bond and stock markets. The third cornerstone is our disciplined and balanced approach to developing investment strategies. The final cornerstone is our ability to implement our strategies through investment processes that are practical and repeatable. Our Partnership Perspective is the centerpiece of our competitive strategy and it gives us an edge in the marketplace where investment managers traditionally operate solely as vendors of performance. Our commitment, in each client relationship, is to elevate our level of responsiveness and understanding of specific objectives to that of a partner. We see ourselves as an extension of our clients' operations where we provide, in addition to performance, significant depth of investment management talent and experience, versatility, and best in class client service. One of the nation's largest minority-owned institutional investment managers, Smith Graham manages approximately $5 billion in assets for a broadly diversified client base.

Recent Transactions
Details Hidden

Eagle Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Eagle Pharmaceuticals, Inc. purchases Eagle Biologics, Inc.

Details Hidden

Eagle Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Escrow Agent

Advised onEagle Pharmaceuticals, Inc. issued USD Common Stock

Auditor

Advised onEagle Pharmaceuticals, Inc. issued USD Common Stock

Underwriter

Advised onEagle Pharmaceuticals, Inc. issued USD Common Stock

Managing Director & Head of North America

Advised onEagle Pharmaceuticals, Inc. issued USD Common Stock

Managing Director

Advised onEagle Pharmaceuticals, Inc. issued USD Common Stock

Associate

Advised onEagle Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Cooley LLP

Consultant

Chief Medical Officer at Pharnext SA

Advisor

Founder at In-Site Communications, Inc.

Clients

Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 46,000 employees worldwide. Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

SymBio Pharmaceuticals Ltd. engages in the pharmaceutical business. It researches, develops, manufactures, and sells new drugs focusing on the areas of oncology, hematology, and autoimmune diseases. The company was founded by Fuminori Yoshida on March 25, 2005 and is headquartered in Tokyo, Japan.

Key Stats and Financials As of 2020
Market Capitalization
$532M
Total Enterprise Value
$576M
Earnings Per Share
$0.87
Revenue
$188M
Three Year Compounded Annual Growth Rate Of Revenue
-7.42%
Total Equity
$186M
Net Profit
$12M
EBITDAMargin
20.09%
Enterprise Value / Sales
3.07x
Enterprise Value EBITDAOperating
15.15x
TEVNet Income
48.08x
Debt TEV
0.07x
EBITDA
$37.7M
Total Debt
$38.2M
Investors
Details Hidden

General Electric Pension Trust is a corporate fund investor in the United States. GE Pension Trust operates as a subsidiary of GE Asset Management Incorporated.

Details Hidden

Former Chief Scientific Officer & Executive Vice President at Eagle Pharmaceuticals, Inc.

Details Hidden

Former Chief Medical Officer at Eagle Pharmaceuticals, Inc.

Suppliers
Lyotropic Therapeutics, Inc. Pharmaceuticals | Ashland, VA

Lyotropic Therapeutics, Inc. provides pharmaceutical products. The company was founded in 1999 and is headquartered in Ashland, VA.

University of Pennsylvania Computer Software | Philadelphia, PA

The University of Pennsylvania (commonly referred to as Penn or UPenn) is a private, Ivy League university, located in Philadelphia, Pennsylvania, United States. Penn considers itself the fourth-oldest institution of higher education in the United States, as well as the first university in the United States with both undergraduate and graduate studies.

Competitors
Viatris, Inc. Pharmaceuticals - Canonsburg, PA

Viatris, Inc. is a healthcare company, which engages in the provision of access to medicines, sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Hikma Pharmaceuticals Plc Pharmaceuticals - London, United Kingdom

Hikma Pharmaceuticals We are committed to improving people’s lives. Through our existing products and pending approvals across our markets, our aim is to provide patients with better access to high-quality, cost-effective medicines in key therapeutic areas. Our vision Our vision is to build Hikma into a world class and leading specialty pharmaceutical company, with presence across the globe. Through organic growth and by acquisitions which are aligned with our strategy, we will continue to develop the business and maintain the high standards of ethics and responsibility which are central to the way we operate.

Endo International Plc Pharmaceuticals - Dublin, Ireland

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment conducts certain manufacturing, quality assurance, R&D and administration functions. The Generic Pharmaceuticals segment conducts certain manufacturing, distribution, quality assurance and administration functions, as well as certain R&D functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Eagle Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Eagle Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Eagle Pharmaceuticals, Inc..